Type 2 diabetes is increasingly common and associated with substantial morbidity and mortality. This study examines trends in the patterns and costs of drug treatment of type 2 diabetes from 1997 to 2012.
Diabetes is a common chronic disease that affects millions of Americans. As of 2011, 11.3% of people 20 years or older had diagnosed and undiagnosed diabetes (1) . Forecasts suggest a continued increase in the population burden of diabetes during the next few decades, with 1 in 3 adults in the U.S. at risk for developing the disease by 2050 (1) . This disease is also associated with considerable economic burden, with annual direct medical expenditures for diabetes treatment and management totaling nearly $250 billion in 2012, representing a 41% increase since 2007 (2, 3) . Although the majority of medical expenditures for diabetes are attributable to hospitalization and physician services, the costs associated with prescription therapies are not trivial, particularly for millions of individuals living on fixed incomes or otherwise burdened by their out-ofpocket prescription costs (4) .
The prevalence and burden of diabetes have made it a target ripe for pharmaceutical development, and during the past decade several important changes in the marketplace have occurred (5) . Early in the 2000s, glitazones were rapidly adopted for use, although subsequent evidence of cardiovascular risks, particularly with rosiglitazone, led to substantial declines in their use during the latter half of the decade (6) . Second, the development and expansion of long-acting insulins that allow patients to take just one injection a day has provided enhanced convenience for patients while achieving more stable glucose control (7) . Additionally, during the past decade, the U.S. Food and Drug Administration (FDA) has approved several new classes of therapies for the treatment of type 2 diabetes, including injectable incretin mimetics (glucagonlike peptide 1 [GLP-1] agonists), dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium glucose cotransporter 2 (SGLT-2) inhibitors. GLP-1 receptor agonists first became available in 2005, followed by DPP-4 inhibitors in 2006. Both classes work via the incretin hormone GLP-1, which increases insulin secretion, delays gastric emptying, and decreases blood glucose levels (8, 9) . Despite their high cost, these therapies have been met with interest, particularly because their novel mechanisms of action allows for their use in combination with other therapies. In addition, GLP-1 agonists have the potential to induce weight loss (10) and both GLP-1 and DPP-4 reduce hypoglycemic risk, though concerns regarding their carcinogenicity and pancreatitis risk have also been raised (11) .
A variety of investigations have examined changes in the treatment of diabetes over the past few decades. These studies have shown evidence of large declines in sulfonylurea use, increases in biguanides, vast fluctuations among glitazones, and evidence of increased costs and complexity of treatment (12) (13) (14) . However, many of these investigations took place only shortly after regulatory communications and prominent scientific reports about the potential cardiovascular risks associated with glitazones and prior to the market diffusion of DPP-4 inhibitors and GLP-1 agonists.
We examined treatment patterns for type 2 diabetes between 1997 and 2012 among office-based physicians in the U.S. In addition to updating prior trends, we were particularly interested in the adoption of DPP-4 inhibitors and GLP-1 agonists as well as how changes in the use of long-acting insulins may have impacted the utilization of oral therapies. We also examined treatment patterns with specific combinations of drugs, treatment complexity, and the aggregate cost of different classes of agents.
RESEARCH DESIGN AND METHODS

Data
We used the IMS Health National Disease and Therapeutic Index (NDTI) to obtain nationally representative diagnostic and prescribing information on patients treated by office-based physicians in the continental U.S. The NDTI sample consists of office-based physicians selected from the master lists of the American Medical Association and the American Osteopathic Association, which include both members and nonmembers of these organizations. About 3,500 physicians participate in data collection on two randomly assigned consecutive workdays in each calendar quarter. IMS Health uses a two-stage stratified cluster design, based on geographic location and physician specialty, to generate national projections from these data.
During each day of participation, physicians complete a form for each consecutive patient encounter. Each encounter form includes basic patient demographic information as well as information about patient diagnoses and treatments. Diagnostic information is captured using a six-digit taxonomic code that is similar to information contained within the ICD-9. We focused on visits for type 2 diabetes, and limited our analyses to individuals 35 years or older to increase the specificity of our method of identification as well as to replicate our prior approach (11). Our primary outcome was a "treatment visit," defined as a visit for a patient where one or more pharmacotherapy was used for treatment of diabetes. A single patient encounter may generate multiple treatment visits, since each product dispensed generates a separate treatment visit. Although NDTI includes encounters that occur outside of ambulatory settings, we excluded the approximately 15% of encounters that occurred by telephone or took place in inpatient or other institutional settings.
We also analyzed data from the IMS Health National Prescription Audit (NPA) from 2008 through 2012. The NPA is an industry standard source of national prescription dispensing activity for all pharmaceutical products and measures what providers prescribe and what is ultimately dispensed to consumers. From the selected pharmacies, IMS collects new and refilled prescriptions for every day of the month. The NPA is derived from a national random computerized sample that as of 2012 was based on a universe of approximately 57,000 retail pharmacies, 327 nongovernmental mail service pharmacy outlets, and 3,000 long-term care pharmacies, including nursing homes and nursing home providers. Information on estimated total expenditures (consumer plus insurance) for these dispensed medications is reported as part of the administrative systems used by pharmacies to bill consumers and health insurers for these products. Because these data do not provide diagnostic information about the patient receiving the prescription, the cost information generated applies to all possible uses of these medications, including type 1 and type 2 diabetes, as well as any offlabel medication uses. We accounted for inflation by adjusting dollars to reflect 2008 values using the consumer price index inflation calculator provided by the U.S. Bureau of Labor Statistics (15) .
Analyses
We used descriptive statistics to evaluate trends in the utilization of each therapy of interest. We focused on eight medication classes depicted in Table 1 : sulfonylureas (glucotrol XL), biguanides (metformin HCl), glitazones (pioglitazone), DPP-4 inhibitors (sitagliptin), incretins (liraglutide), meglitinides (repaglinide), a-glucosidase inhibitors (acarbose), insulins (insulin glargine), and amylin analogs (pramlintide). We classified drugs within these therapeutic groups based on their chemical composition, using the IMS Health Universal System of Classification (USC) codes. We counted fixed-dose combination products as contributing to each of their constituent classes when computing total compounds; for example, a combination product such as Janumet (sitagliptin and metformin) was counted as contributing once to biguanides and once to DPP-4 inhibitors. Thus, our analysis of trends in DPP-4 use includes visits where they were used as fixeddose combination products containing DPP-4 inhibitors as well as where they were used as an individual product. We also calculated therapeutic intensity, which we assessed by dividing total number of compounds used by the total number of unique treatment visits in a given year. For these calculations, a visit with a fixed-dose combination would be considered as similarly intense as a treatment where two separate products were used, since both would similarly reflect the use of two compounds during a single visit. For estimates from the NDTI, we calculated 95% CIs using tables of relative standard errors that are derived accounting for the survey's complex sampling design. Because the NPA is based on such a large sample of pharmacies, the uncertainty surrounding estimates of national prescription expenditures is small.
RESULTS
Trends in Treatment Visits
There was a steady rise in ambulatory treatment visits for type 2 diabetes, from 23.6 million (95% CI
Changes in Medication Classes Used as Diabetes Therapy
Use of sulfonylureas has declined continuously since 1997, when they were the most prescribed class of medicines accounting for about 61% (95% CI 57-69) of all treatment visits; by 2012, sulfonylureas were used in just 22% (20-26) of diabetes treatment visits (Fig. 1) . Glitazone treatment visits increased from 1997 to 2005, peaking at 41% of all visits, then declined to 16% (14) (15) (16) (17) (18) in 2012, at which point almost 96% of glitazone treatment visits involved pioglitazone products. Metformin use has increased steadily from 24% (21-27) of treatment visits in 1997 to 53% (51-55) in 2012.
Since the approval of the first DPP-4 inhibitor, sitagliptin (Januvia)
Treatment Patterns Using Insulins
As a class, insulin use has remained relatively stable, accounting for 27% (95% CI 25-29) of treatment visits in 1997 and 26% (23) (24) (25) (26) (27) (Fig. 2) . Conversely, short-acting insulin use has doubled over that same time period, while use of long-acting insulin has increased from less than 1% of treatment visits (1997) to almost 18% of all treatment visits (2012).
Mono-and Dual-Therapy and Intensity of Treatment
Since 1997, the overall proportion of visits where a single treatment, including a single fixed-dose combination treatment, was used has declined by almost 30%, representing 42% of treatment visits in 2012 (Table 2) . When combination products are excluded, this decreased further to only 35% of treatment visits. Of the 14.9 million treatment visits where a single compound was used in 2012, biguanide (53% [95% CI 51-55]) and insulin (15% [13] [14] [15] [16] [17] ) visits were most common, with fewer accounted for by sulfonylureas (13% [12] [13] [14] ), DPP-4 inhibitors (10% [9] [10] [11] ), or other products (Table 3 ).
In 1997, 9.6 million treatment visits (41% of all treatment visits) included two or more compounds. By 2012, this had increased to 18.2 million treatment visits, more than 58% of all treatment visits. Approximately one-third of these visits were represented by the combination of biguanides and sulfonylureas (31% [29] [30] [31] [32] [33] ), while approximately one-fifth were accounted for by biguanides and DPP-4 inhibitors (20% [18] [19] [20] [21] [22] 
Medication Expenditures
Since 2008, retail pharmacy expenditures increased by 61%, reaching almost $22 billion by 2012 after adjustment for inflation. This increase was driven primarily by insulins and, to a lesser degree, DPP-4 inhibitors (Fig. 3) . As a class, insulin's total retail sales have more than doubled, primarily due to increases in long-and shortacting insulins (data not shown). 
CONCLUSIONS
In this study of a nationally representative audit of ambulatory practice in the U.S., we found substantial changes in treatment of type 2 diabetes during the past decade. These changes include continued declines in the use of sulfonylureas and glitazones, a plateauing of biguanide use after steady increases until 2010, and stable insulin use that is increasingly dominated by long-acting insulin glargine. We also found rapid increases Our findings regarding DPP-4 inhibitors and GLP-1 agonists are noteworthy. Both of these classes of agents produce significant improvements to glycemic control, particularly in patients who are not well controlled with first-line oral agents (16) (17) (18) , although there is some evidence that GLP-1s are more efficacious than DPP-4 inhibitors with respect to glycemic end points (19) . There is also an increasingly amount of scientific information available about their association with cardiovascular outcomes (20, 21) . Clinical guidelines by professional societies have also supported earlier use of these therapies (11, 22, 23) , and declines in glitazones may have also further facilitated their adoption (12) . Despite this, there is ongoing disagreement regarding the degree to which agents acting through the GLP-1 pathway are associated with pancreatitis and pancreatic cancer (24, 25) .
Biguanides continue to be the cornerstone of diabetes management; by 2012, more than 50% of treatment visits were accounted for by metformin. Conversely, we found continued reductions in glitazones and sulfonylureas. In the case of glitazones, the use of these products steadily increased since the market introduction of rosiglitazone and pioglitazone in 1999, until they peaked in 2005. The ensuing decrease of all glitazone use was strongly correlated with the publication and FDA warning of increased cardiovascular risk with rosiglitazone. Though these risks continue to be debated (26) , the product label continues to carry warnings and there is no evidence of any substantial recovery of market share by these products. In contrast to the glitazones, sulfonylureas use began to wane earlier, in the mid-1990s; these declines have occurred for a number of reasons, including their risks of hypoglycemia, association with weight gain, and minimal marketing and promotion (17, 27 Our study has several limitations. First, the NDTI provides limited information from which to judge the clinical appropriateness of the therapies that In conclusion, declining sulfonylurea and glitazone use has been offset by increases in DPP-4 inhibitor use and, to a lesser degree, use of GLP-1 agonists.
Treatment of type 2 diabetes has grown in complexity and cost while older treatments continue to be replaced or supplemented by newer therapies. It is critical to monitor these patterns as additional evidence is developed regarding the comparative effectiveness as well as potential risks of newer therapies, especially injectable incretin mimetics (GLP-1 agonists), DPP-4 inhibitors, and SGLT-2 inhibitors.
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